๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 16 Birmingham 6 Glasgow 5 Sheffield 5 Newcastle upon Tyne 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London16 Birmingham6 Glasgow5 Sheffield5 Newcastle upon Tyne4
All 27 cities
Target enrolment
to
16 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated
Phase 2
30
Birmingham, London, Salford
2026-05-13
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
By invitation
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT06926621Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated
Phase 2
44
Glasgow, London, Sheffield
2025-04-28
Active, closed
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Observational
401
Birmingham, London, Newcastle upon Tyne, Sheffield
2024-12-19
Active, closed
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
50
Cardiff, Leeds, Liverpool, London, Southampton
2024-11-21
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
Vertex Pharmaceuticals Incorporated
Phase 2
300
Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield
2024-10-18
Active, closed
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
Glasgow, London, Salford, Sheffield
2024-02-20
By invitation
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
NCT05844449Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
174
Cardiff, London
2023-08-11
Active, closed
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 1/2
26
Cambridge, Glasgow, London, Manchester, Penarth, Southampton
2023-02-27
Active, closed
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
210
Cardiff, London
2022-06-21
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent ฮฒ-Thalassemia (TDT)
NCT05356195Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases
Vertex Pharmaceuticals Incorporated
Phase 3
16
London
2022-05-03
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies
Vertex Pharmaceuticals Incorporated
Phase 3
13
London
2022-05-02
Recruiting
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Recruiting
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Vertex Pharmaceuticals Incorporated
Phase 3
57
Headington, Edinburgh, London, Newcastle upon Tyne
2021-03-29
By invitation
A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases
Vertex Pharmaceuticals Incorporated
Phase 3
160
London
2021-01-20
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.